• 1
    Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 1910; 6: 517521.
  • 2
    Konotey-Ahulu FI. The sickle cell diseases. Clinical manifestations including the “sickle crisis”. Arch Intern Med 1974; 133: 611619.
  • 3
    Yater WM,Hansmann GH. Sickle-cell anemia: A new cause of cor pulmonale: Report of two cases with numerous disseminated occlusions of the small pulmonary arteries. Am J Med Sci 1936; 191: 474484.
  • 4
    Hebbel RP,Schwartz RS,Mohandas N. The adhesive sickle erythrocyte: Cause and consequence of abnormal interactions with endothelium, monocytes/macrophages and model membranes. Clin Haematol 1985; 14: 141161.
  • 5
    Kaul DK,Fabry ME,Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiological implications. Proc Natl Acad Sci USA 1989; 86: 33563360.
  • 6
    Ballas SK. Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. Am J Hematol 1991; 36: 122130.
  • 7
    Schnog JJ,Lard LR,Rojer RA, et al. New concepts in assessing sickle cell disease severity. Am J Hematol 1998; 58: 6166.
  • 8
    Alexander N,Higgs D,Dover G,Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol 2004; 126: 606611.
  • 9
    Gladwin MT,Sachdev V,Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886895.
  • 10
    Morris CR,Kato GJ,Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA 2005; 294: 8190.
  • 11
    Reiter CD,Wang X,Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8: 13831389.
  • 12
    Kato GJ,McGowan VR,Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. Blood 2006; 107: 22792285.
  • 13
    Kato GJ,Gladwin MT,Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21: 3747.
  • 14
    Aird WC. Endothelial Biomedicine. New York: Cambridge University Press; 2007.
  • 15
    Hebbel RP,Osarogiagbon R,Kaul D. The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy. Microcirculation 2004; 11: 129151.
  • 16
    Solovey A,Lin Y,Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337: 15841590.
  • 17
    Nath KA,Grande JP,Haggard JJ, et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 2001; 158: 893903.
  • 18
    Wood K,Russell J,Hebbel RP,Granger DN. Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation 2004; 11: 377385.
  • 19
    Tomer A,Harker LA,Kasey S,Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137: 398407.
  • 20
    Solovey A,Kollander R,Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004; 104: 840846.
  • 21
    Francis RBJr,Hebbel RP. Hemostasis. In: EmburySH, HebbelRP, MohandasN, SteinbergMH, editors. Sickle Cell Disease. New York: Raven Press; 1994. pp 229310.
  • 22
    Belhassen L,Pelle G,Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001; 97: 15841589.
  • 23
    Nath KA,Shah V,Haggard JJ, et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1949R1955.
  • 24
    Nath KA,Katusic ZS,Gladwin MT. The perfusion paradox and vascular instability in sickle cell disease. Microcirculation 2004; 11: 179193.
  • 25
    Osarogiagbon UR,Choong S,Belcher JD, et al. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000; 96: 314320.
  • 26
    Kaul DK,Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 2000; 106: 411420.
  • 27
    Hoppe C,Klitz W,Noble J, et al. Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 2003; 101: 28652869.
  • 28
    Sebastiani P,Ramoni MF,Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37: 435440.
  • 29
    Chang Milbauer L,Wei P,Enenstein J, et al. Genetic endothelial systems biology of sickle stroke risk. Blood 2008; 111: 38723879.
  • 30
    Ashley-Koch AE,Elliott L,Kail ME, De Castro LM, Jonassaint J, Jackson TL, Price J, Ataga KI, Levesque MC, Weinberg JB, Orringer EP, Collins A, Vance JM, Telen MJ. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 2008; 111: 57215726.
  • 31
    Eaton WA,Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood 1987; 70: 12451266.
  • 32
    Carden DL,Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000; 190: 255266.
  • 33
    Solovey AA,Solovey AN,Harkness J,Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: A pilot study. Blood 2001; 97: 19371941.
  • 34
    Furchgott RF,Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373376.
  • 35
    Ignarro LJ,Byrns RE,Buga GM,Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987; 61: 866879.
  • 36
    Palmer RM,Ashton DS,Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664666.
  • 37
    Panza JA,Casino PR,Kilcoyne CM,Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 14681474.
  • 38
    De Caterina R,Libby P,Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 6068.
  • 39
    Doherty DH,Doyle MP,Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 1998; 16: 672676.
  • 40
    Schechter AN,Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 2003; 348: 14831485.
  • 41
    Reiter CD,Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 2003; 10: 99107.
  • 42
    Yu B,Raher MJ,Volpato GP, et al. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 2008; 117: 19821990.
  • 43
    Gladwin MT,Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359: 22542265.
  • 44
    Landburg PP,Teerlink T,Muskiet FA, et al. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. Am J Hematol 2008; 83: 577579.
  • 45
    Landburg PP,Teerlink T,van Beers EJ, et al. Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension. Haematologica 2008; 93: 14101412.
  • 46
    Kato GJ,Wang Z,Machado RF, et al. Endogenous nitric oxide synthase inhibitors in sickle cell disease: Abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 2009; 145: 506513.
  • 47
    Yuditskaya S,Tumblin A,Hoehn GT, et al. Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood 2009; 113: 11221128.
  • 48
    Rother RP,Bell L,Hillmen P,Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005; 293: 16531662.
  • 49
    Raghavachari N,Xu X,Harris A, Villagra J, Logun C, Barb J, Solomon MA, Suffredini AF, Danner RL, Kato G, Munson PJ, Morris SMJr, Gladwin MT. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation 2007; 115: 15511562.
  • 50
    Villagra J,Shiva S,Hunter LA, et al. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension and nitric oxide scavenging by cell-free hemoglobin. Blood 2007; 110: 21662172.
  • 51
    Ataga KI,Moore CG,Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008; 93: 2026.
  • 52
    van Beers EJ,Spronk HM,Ten Cate H, et al. No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. Haematologica 2008; 93: e42e44.
  • 53
    Hsu LL,Champion HC,Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007; 109: 30883098.
  • 54
    Gramaglia I,Sobolewski P,Meays D, et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med 2006; 12: 14171422.
  • 55
    Hillmen P,Muus P,Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 41234128.
  • 56
    Yeo TW,Lampah DA,Gitawati R, et al. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med 2007; 204: 26932704.
  • 57
    Ataga KI,Moore CG,Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: A longitudinal study. Br J Haematol 2006; 134: 109115.
  • 58
    De Castro LM,Jonassaint JC,Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008; 83: 1925.
  • 59
    Castro O,Hoque M,Brown BD. Pulmonary hypertension in sickle cell disease: Cardiac catheterization results and survival. Blood 2003; 101: 12571261.
  • 60
    Ataga KI,Sood N,De GG, et al. Pulmonary hypertension in sickle cell disease. Am J Med 2004; 117: 665669.
  • 61
    Machado RF,Anthi A,Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006; 296: 310318.
  • 62
    Vichinsky EP. Pulmonary hypertension in sickle cell disease. N Engl J Med 2004; 350: 857859.
  • 63
    Machado RF,Gladwin MT. Chronic sickle cell lung disease: New insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol 2005; 129: 449464.
  • 64
    McQuillan BM,Picard MH,Leavitt M,Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001; 104: 27972802.
  • 65
    Onyekwere OC,Campbell A,Teshome M, et al. Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr Cardiol 2008; 29: 309312.
  • 66
    Kato GJ,Onyekwere OC,Gladwin MT. Pulmonary hypertension in sickle cell disease: Relevance to children. Pediatr Hematol Oncol 2007; 24: 159170.
  • 67
    Minniti CP,Sable C,Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: Association with hemolysis and hemoglobin oxygen desaturation. Haematologica 2009; 94: 340347.
  • 68
    Sedrak A,Rao SP,Miller ST, et al. A prospective appraisal of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol 2009; 31: 97100.
  • 69
    Pashankar FD,Carbonella J,Bazzy-Asaad A,Friedman A. Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. Br J Haematol 2009; 144: 736741.
  • 70
    Lee MT,Rosenzweig EB,Cairo MS. Pulmonary hypertension in sickle cell disease. Clin Adv Hematol Oncol 2007; 5: 645653, 585.
  • 71
    Ambrusko SJ,Gunawardena S,Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer 2006; 47: 907913.
  • 72
    Hagar RW,Michlitsch JG,Gardner J, et al. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol 2008; 140: 104112.
  • 73
    Liem RI,Nevin MA,Prestridge A, et al. Tricuspid regurgitant jet velocity elevation and its relationship to lung function in pediatric sickle cell disease. Pediatr Pulmonol 2009; 44: 281289.
  • 74
    Adams RJ,McKie VC,Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 511.
  • 75
    Olnes M,Chi A,Haney C, May R, Minniti C, Taylor J 6th, Kato GJ. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol, in press.
  • 76
    Kato GJ,Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008; 300: 26382646.
  • 77
    Kato GJ. Novel small molecule therapeutics for sickle cell disease: Nitric oxide, carbon monoxide, nitrite, and apolipoprotein a-I. Hematology Am Soc Hematol Educ Program 2008; 2008: 186192.
  • 78
    Klings ES,Anton Bland D,Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: Clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol 2008; 83: 547553.
  • 79
    Caldas MC,Meira ZA,Barbosa MM. Evaluation of 107 patients with sickle cell anemia through tissue Doppler and myocardial performance index. J Am Soc Echocardiogr 2008; 21: 11631167.
  • 80
    Kanadasi M,Akpinar O,Cayli M, et al. Frequency of diastolic dysfunction in patients with sickle cell anaemia: A tissue Doppler imaging study. Acta Cardiol 2005; 60: 471476.
  • 81
    Lewis JF,Maron BJ,Castro O,Moosa YA. Left ventricular diastolic filling abnormalities identified by Doppler echocardiography in asymptomatic patients with sickle cell anemia. J Am Coll Cardiol 1991; 17: 14731478.
  • 82
    Sachdev V,Machado RF,Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol 2007; 49: 472479.
  • 83
    Anthi A,Machado RF,Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 2007; 175: 12721279.
  • 84
    Machado RF,Mack AK,Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol 2007; 136: 319325.
  • 85
    Mekontso Dessap A,Leon R,Habibi A, et al. Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2008; 177: 646653.
  • 86
    Ohene-Frempong K,Weiner SJ,Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998; 91: 288294.
  • 87
    Rothman SM,Fulling KH,Nelson JS. Sickle cell anemia and central nervous system infarction: A neuropathological study. Ann Neurol 1986; 20: 684690.
  • 88
    Haque AK,Gokhale S,Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: A clinicopathologic study of 20 cases. Hum Pathol 2002; 33: 10371043.
  • 89
    Kato GJ,Hsieh M,Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol 2006; 81: 503510.
  • 90
    Bernaudin F,Verlhac S,Chevret S, et al. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood 2008; 112: 43144317.
  • 91
    Hsu LL,Miller ST,Wright E, et al. Alpha thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol 2003; 25: 622628.
  • 92
    Akgul F,Yalcin F,Seyfeli E, et al. Pulmonary hypertension in sickle-cell disease: Comorbidities and echocardiographic findings. Acta Haematol 2007; 118: 5360.
  • 93
    Nolan VG,Adewoye A,Baldwin C, et al. Sickle cell leg ulcers: Associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006; 133: 570578.
  • 94
    Nolan VG,Wyszynski DF,Farrer LA,Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood 2005; 106: 32643267.
  • 95
    Burnett AL,Bivalacqua TJ,Champion HC,Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 2006; 67: 10431048.
  • 96
    Burnett AL,Bivalacqua TJ,Champion HC,Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006; 3: 10771084.
  • 97
    Champion HC,Bivalacqua TJ,Takimoto E, et al. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 2005; 102: 16611666.
  • 98
    Bialecki ES,Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med 2002; 113: 252.
  • 99
    Hagar RW,Michlitsch JG,Gardner J, et al. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol 2008; 140: 104112.
  • 100
    Brittain JE,Parise LV. The alpha4beta1 integrin in sickle cell disease. Transfus Clin Biol 2008; 15: 1922.
  • 101
    Canalli AA,Franco-Penteado CF,Saad ST, et al. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica 2008; 93: 605609.
  • 102
    Haynes JJr,Obiako B,Hester RB, et al. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium. Am J Physiol Heart Circ Physiol 2008; 294: H379H385.
  • 103
    Chang J,Shi PA,Chiang EY,Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008; 111: 915923.
  • 104
    Kasschau MR,Barabino GA,Bridges KR,Golan DE. Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 1996; 87: 771780.
  • 105
    Boghossian SH,Nash G,Dormandy J,Bevan DH. Abnormal neutrophil adhesion in sickle cell anaemia and crisis: Relationship to blood rheology. Br J Haematol 1991; 78: 437441.
  • 106
    Inwald DP,Kirkham FJ,Peters MJ, et al. Platelet and leucocyte activation in childhood sickle cell disease: Association with nocturnal hypoxaemia. Br J Haematol 2000; 111: 474481.
  • 107
    Brittain JE,Knoll CM,Ataga KI, et al. Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1. Br J Haematol 2008; 141: 872881.
  • 108
    Belcher JD,Marker PH,Weber JP, et al. Activated monocytes in sickle cell disease: Potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000; 96: 24512459.
  • 109
    Lee SP,Ataga KI,Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell anemia: Potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 16261631.
  • 110
    Wun T,Paglieroni T,Tablin F, et al. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 1997; 129: 507516.
  • 111
    Nolan VG,Baldwin C,Ma Q, et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol 2005; 128: 266272.
  • 112
    Elliott L,Ashley-Koch AE,De Castro L, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol 2007; 137: 262267.
  • 113
    Adewoye AH,Nolan VG,Ma Q, et al. Association of polymorphisms of IGF1R and genes in the transforming growth factor- beta /bone morphogenetic protein pathway with bacteremia in sickle cell anemia. Clin Infect Dis 2006; 43: 593598.
  • 114
    Nagel RL,Lawrence C. The distinct pathobiology of sickle cell-hemoglobin C disease. Therapeutic implications. Hematol Oncol Clin North Am 1991; 5: 433451.
  • 115
    Serjeant GR. Fetal haemoglobin in homozygous sickle cell disease. Clin Haematol 1975; 4: 109122.
  • 116
    Atweh GF,Forget BG. Clinical and molecular correlations in the sickle/beta+-thalassemia syndrome. Am J Hematol 1987; 24: 3136.
  • 117
    De Ceulaer K,Higgs DR,Weatherall DJ, et al. alpha-Thalassemia reduces the hemolytic rate in homozygous sickle-cell disease. N Engl J Med 1983; 309: 189190.
  • 118
    Embury SH,Dozy AM,Miller J, et al. Concurrent sickle-cell anemia and alpha-thalassemia: Effect on severity of anemia. N Engl J Med 1982; 306: 270274.
  • 119
    Ataga KI,Smith WR,De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008; 111: 39913997.
  • 120
    Schaer DJ,Alayash AI,Buehler PW. Gating the radical hemoglobin to macrophages: The anti-inflammatory role of CD163, a scavenger receptor. Antioxid Redox Signal 2007; 9: 991999.
  • 121
    Kristiansen M,Graversen JH,Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409: 198201.
  • 122
    Lanaro C,Franco-Penteado CF,Albuqueque DM, et al. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 2009; 85: 235242.
  • 123
    Belcher JD,Mahaseth H,Welch TE, et al. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 2006; 116: 808816.
  • 124
    Ryter SW,Otterbein LE,Morse D,Choi AM. Heme oxygenase/carbon monoxide signaling pathways: Regulation and functional significance. Mol Cell Biochem 2002; 234/235: 249263.
  • 125
    Walter PB,Fung EB,Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006; 135: 254263.
  • 126
    Hebbel RP. Auto-oxidation and a membrane-associated ‘Fenton reagent’: A possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 1985; 14: 129140.
  • 127
    Repka T,Hebbel RP. Hydroxyl radical formation by sickle erythrocyte membranes: Role of pathologic iron deposits and cytoplasmic reducing agents. Blood 1991; 78: 27532758.
  • 128
    Kaul DK,Liu XD,Choong S, et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2004; 287: H293H301.
  • 129
    Aslan M,Ryan TM,Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001; 98: 1521515220.
  • 130
    Aslan M,Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease--mechanisms and consequences. Cell Mol Biol (Noisy-le-grand) 2004; 50: 95105.
  • 131
    Kelley EE,Batthyany CI,Hundley NJ, et al. Nitro-oleic acid, a novel and irreversible inhibitor of xanthine oxidoreductase. J Biol Chem 2008; 283: 3617636184.
  • 132
    Wood KC,Hebbel RP,Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J 2005; 19: 989991.
  • 133
    Xia Y,Dawson VL,Dawson TM, et al. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996; 93: 67706774.
  • 134
    Heinzel B,John M,Klatt P, et al. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992; 281(Pt 3): 627630.
  • 135
    Schnog JJ,Jager EH,van der Dijs FP, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol 2004; 83: 371375.
  • 136
    Lopez BL,Kreshak AA,Morris CR, et al. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 2003; 120: 532534.
  • 137
    Waugh WH,Knupp CL,Liles DK. Undetectable plasma L-arginine level before visible hemolysis in thrombotic thrombocytopenic purpura. Am J Hematol 1999; 61: 216.
  • 138
    Azizi E,Dror Y,Wallis K. Arginase activity in erythrocytes of healthy and ill children. Clin Chim Acta 1970; 28: 391396.
  • 139
    Morris CR,Morris SMJr,Hagar W, et al. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168: 6369.
  • 140
    Morris CR,Vichinsky EP,Van WJ, et al. Hydroxyurea and arginine therapy: Impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol 2003; 25: 629634.
  • 141
    Moens AL,Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 2006; 26: 24392444.
  • 142
    Gorren AC,Mayer B. Tetrahydrobiopterin in nitric oxide synthesis: A novel biological role for pteridines. Curr Drug Metab 2002; 3: 133157.
  • 143
    Katusic ZS,d'Uscio LV,Nath KA. Vascular protection by tetrahydrobiopterin: Progress and therapeutic prospects. Trends Pharmacol Sci 2009; 30: 4854.
  • 144
    Morris CR,Suh JH,Hagar W, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 2008; 111: 402410.
  • 145
    El Rassi F,Cappellini MD,Inati A,Taher A. Beta-thalassemia intermedia: An overview. Pediatr Ann 2008; 37: 322328.